Floatz logo

Cis-Diamminedichloroplatinum Ii

Ovarian Mucinous Adenocarcinoma

Floatz Rating
BB70/100
Confidence
Indicative
v0.2
Sponsor
Ohio State University Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Clinical EvidenceClinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57
ConfUnderlying methodology share. Confidence: three dots confirmed, two provisional, one indicative.
Competitive PositionCompetitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95
ConfUnderlying methodology share. Confidence: three dots confirmed, two provisional, one indicative.
Scientific Foundation
NR
Conf
Development Feasibility
NR
Conf
Commercial Opportunity
NR
Conf
IP & Exclusivity
NR
Conf
Manufacturing & Supply
NR
Conf